213 related articles for article (PubMed ID: 22087289)
1. The antiangiogenic 16K prolactin impairs functional tumor neovascularization by inhibiting vessel maturation.
Nguyen NQ; Castermans K; Berndt S; Herkenne S; Tabruyn SP; Blacher S; Lion M; Noel A; Martial JA; Struman I
PLoS One; 2011; 6(11):e27318. PubMed ID: 22087289
[TBL] [Abstract][Full Text] [Related]
2. The 16-kilodalton N-terminal fragment of human prolactin is a potent inhibitor of angiogenesis.
Clapp C; Martial JA; Guzman RC; Rentier-Delure F; Weiner RI
Endocrinology; 1993 Sep; 133(3):1292-9. PubMed ID: 7689950
[TBL] [Abstract][Full Text] [Related]
3. The angiostatic protein 16K human prolactin significantly prevents tumor-induced lymphangiogenesis by affecting lymphatic endothelial cells.
Kinet V; Castermans K; Herkenne S; Maillard C; Blacher S; Lion M; Noël A; Martial JA; Struman I
Endocrinology; 2011 Nov; 152(11):4062-71. PubMed ID: 21862622
[TBL] [Abstract][Full Text] [Related]
4. Inhibition of tumor growth and metastasis establishment by adenovirus-mediated gene transfer delivery of the antiangiogenic factor 16K hPRL.
Nguyen NQ; Cornet A; Blacher S; Tabruyn SP; Foidart JM; Noël A; Martial JA; Struman I
Mol Ther; 2007 Dec; 15(12):2094-100. PubMed ID: 17726458
[TBL] [Abstract][Full Text] [Related]
5. Molecular targeting of antiangiogenic factor 16K hPRL inhibits oxygen-induced retinopathy in mice.
Pan H; Nguyen NQ; Yoshida H; Bentzien F; Shaw LC; Rentier-Delrue F; Martial JA; Weiner R; Struman I; Grant MB
Invest Ophthalmol Vis Sci; 2004 Jul; 45(7):2413-9. PubMed ID: 15223825
[TBL] [Abstract][Full Text] [Related]
6. Antiangiogenic liposomal gene therapy with 16K human prolactin efficiently reduces tumor growth.
Kinet V; Nguyen NQ; Sabatel C; Blacher S; Noël A; Martial JA; Struman I
Cancer Lett; 2009 Nov; 284(2):222-8. PubMed ID: 19473755
[TBL] [Abstract][Full Text] [Related]
7. Expression of the antiangiogenic factor 16K hPRL in human HCT116 colon cancer cells inhibits tumor growth in Rag1(-/-) mice.
Bentzien F; Struman I; Martini JF; Martial J; Weiner R
Cancer Res; 2001 Oct; 61(19):7356-62. PubMed ID: 11585777
[TBL] [Abstract][Full Text] [Related]
8. The antiangiogenic factor, 16-kDa human prolactin, induces endothelial cell cycle arrest by acting at both the G0-G1 and the G2-M phases.
Tabruyn SP; Nguyen NQ; Cornet AM; Martial JA; Struman I
Mol Endocrinol; 2005 Jul; 19(7):1932-42. PubMed ID: 15746189
[TBL] [Abstract][Full Text] [Related]
9. Cathepsin D processes human prolactin into multiple 16K-like N-terminal fragments: study of their antiangiogenic properties and physiological relevance.
Piwnica D; Touraine P; Struman I; Tabruyn S; Bolbach G; Clapp C; Martial JA; Kelly PA; Goffin V
Mol Endocrinol; 2004 Oct; 18(10):2522-42. PubMed ID: 15192082
[TBL] [Abstract][Full Text] [Related]
10. The angiostatic 16K human prolactin overcomes endothelial cell anergy and promotes leukocyte infiltration via nuclear factor-kappaB activation.
Tabruyn SP; Sabatel C; Nguyen NQ; Verhaeghe C; Castermans K; Malvaux L; Griffioen AW; Martial JA; Struman I
Mol Endocrinol; 2007 Jun; 21(6):1422-9. PubMed ID: 17405903
[TBL] [Abstract][Full Text] [Related]
11. 16K human prolactin inhibits vascular endothelial growth factor-induced activation of Ras in capillary endothelial cells.
D'Angelo G; Martini JF; Iiri T; Fantl WJ; Martial J; Weiner RI
Mol Endocrinol; 1999 May; 13(5):692-704. PubMed ID: 10319320
[TBL] [Abstract][Full Text] [Related]
12. The antiangiogenic factor 16K PRL induces programmed cell death in endothelial cells by caspase activation.
Martini JF; Piot C; Humeau LM; Struman I; Martial JA; Weiner RI
Mol Endocrinol; 2000 Oct; 14(10):1536-49. PubMed ID: 11043570
[TBL] [Abstract][Full Text] [Related]
13. The antiangiogenic factor 16K human prolactin induces caspase-dependent apoptosis by a mechanism that requires activation of nuclear factor-kappaB.
Tabruyn SP; Sorlet CM; Rentier-Delrue F; Bours V; Weiner RI; Martial JA; Struman I
Mol Endocrinol; 2003 Sep; 17(9):1815-23. PubMed ID: 12791771
[TBL] [Abstract][Full Text] [Related]
14. Sprouty1, a new target of the angiostatic agent 16K prolactin, negatively regulates angiogenesis.
Sabatel C; Cornet AM; Tabruyn SP; Malvaux L; Castermans K; Martial JA; Struman I
Mol Cancer; 2010 Sep; 9():231. PubMed ID: 20813052
[TBL] [Abstract][Full Text] [Related]
15. Tumor vessel development and maturation impose limits on the effectiveness of anti-vascular therapy.
Gee MS; Procopio WN; Makonnen S; Feldman MD; Yeilding NM; Lee WM
Am J Pathol; 2003 Jan; 162(1):183-93. PubMed ID: 12507901
[TBL] [Abstract][Full Text] [Related]
16. PAI-1 mediates the antiangiogenic and profibrinolytic effects of 16K prolactin.
Bajou K; Herkenne S; Thijssen VL; D'Amico S; Nguyen NQ; Bouché A; Tabruyn S; Srahna M; Carabin JY; Nivelles O; Paques C; Cornelissen I; Lion M; Noel A; Gils A; Vinckier S; Declerck PJ; Griffioen AW; Dewerchin M; Martial JA; Carmeliet P; Struman I
Nat Med; 2014 Jul; 20(7):741-7. PubMed ID: 24929950
[TBL] [Abstract][Full Text] [Related]
17. 16-kDa prolactin inhibits endothelial cell migration by down-regulating the Ras-Tiam1-Rac1-Pak1 signaling pathway.
Lee SH; Kunz J; Lin SH; Yu-Lee LY
Cancer Res; 2007 Nov; 67(22):11045-53. PubMed ID: 18006851
[TBL] [Abstract][Full Text] [Related]
18. Impact of vessel maturation on antiangiogenic therapy in ovarian cancer.
Lu C; Thaker PH; Lin YG; Spannuth W; Landen CN; Merritt WM; Jennings NB; Langley RR; Gershenson DM; Yancopoulos GD; Ellis LM; Jaffe RB; Coleman RL; Sood AK
Am J Obstet Gynecol; 2008 Apr; 198(4):477.e1-9; discussion 477.e9-10. PubMed ID: 18395047
[TBL] [Abstract][Full Text] [Related]
19. Screening assay for blood vessel maturation inhibitors.
Fu C; van der Zwan A; Gerber S; Van Den Berg S; No E; Wang WC; Sheibani N; Carducci MA; Kachhap S; Hammers HJ
Biochem Biophys Res Commun; 2013 Aug; 438(2):364-9. PubMed ID: 23892038
[TBL] [Abstract][Full Text] [Related]
20. Pericytes and vessel maturation during tumor angiogenesis and metastasis.
Raza A; Franklin MJ; Dudek AZ
Am J Hematol; 2010 Aug; 85(8):593-8. PubMed ID: 20540157
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
